EADO 14th European School of Dermato-Oncology 2026

+ Target Audience: dermatologists, medical oncologists, surgical oncologists, radiation oncologists, dermatopathologists

+ Information:

The EADO initiates for the fourteenth time a course dedicated to fundamentals in skin cancer targeted to specialists and residents in the final phase of their resident program. They will benefit a comprehensive and updated course to improve their decision-making process for the management of all types and stages of skin cancer, from diagnosis, primary treatment and adjuvant treatment, to the management of loco-regional disease and distant metastatic disease.

Target Audience

This 2-day educational course targets doctors who are actively involved in the treatment of skin cancer. Dermatologists or other specialists who have completed specialist training, or residents in the final year of their training program, are likely to gain the most from this course.

Best for dermatologists, medical oncologists, surgical oncologists, radiation oncologists, and dermatopathologists.

Learning Objectives

Upon completion of this program, participants will be able to:

• Understand the fundamental epidemiology, genetic predispositions, and molecular biology driving the pathogenesis of various skin cancers.

• Apply advanced non-invasive diagnostic techniques, such as dermoscopy and reflectance confocal microscopy, to accurately identify and differentiate cutaneous malignancies.

• Implement the latest evidence-based, multidisciplinary treatment guidelines for early, high-risk, and metastatic skin cancers, integrating surgical, radiotherapeutic, and systemic modalities.

• Optimize the use of modern systemic treatments, including immune checkpoint inhibitors and targeted therapies, while effectively recognizing and managing their specific adverse events.

• Navigate the complex diagnostic and therapeutic pathways for rare cutaneous tumors, including Merkel cell carcinoma and cutaneous lymphomas.

+ Topics:

• COURSE 1 What should you know about the mode of action of Immune Checkpoint Inhibition and Targeted Therapies
• COURSE 2 AI-assisted diagnostics for skin cancer standards and innovations
• COURSE 3 Access to drug innovations in Europe
• COURSE 4 Adjuvant therapies across skin cancer
• COURSE 5 Neoadjuvant therapies across skin cancers the new standards-of-care
• COURSE 6 European guideline changes for skin cancer patients
• COURSE 7 Common adverse events of skin cancer drugs (ICI, TT, HHI, chemo, etc)
• COURSE 8 Challenging side effects of skin cancer drugs expert panel discussion of 4 cases
• COURSE 9 Challenging clinical situations in melanoma and keratinocyte cancers
• COURSE 10 What should you know about running a clinical trial
• Opening Session